
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc has experienced a significant increase in cash and investments, reaching $16.6 million, bolstered by advances from the Cancer Prevention and Research Institute of Texas (CPRIT) and strong market activities, which have aided the company's compliance with Nasdaq listing standards. The company is advancing its CNSide Diagnostic platform, enhancing its manufacturing capability and commercial readiness, while also benefiting from interest from NCI-Designated Cancer Centers, indicating a strong adoption potential in the market. Furthermore, Plus Therapeutics's operational advancements, including receiving a substantial grant for leptomeningeal metastases research and achieving CLIA certification for its laboratory, solidify its future growth prospects and reimbursement infrastructure.
Bears say
Plus Therapeutics Inc reported grant revenue of $1.4 million but experienced a significant total operating loss of $4.5 million, culminating in a net loss of $4.4 million. The company faces several risks that could hinder its financial stability, including the potential failure of its product candidates to demonstrate safety and efficacy in clinical trials, challenges in gaining regulatory approval, and competition within the market. Additionally, the pro forma EPS of $0.02 contrasted starkly with estimates of $(0.13) and consensus expectations of $(0.12), indicating a gap that raises concerns regarding the company's financial performance and outlook.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares